Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 10 week open-label pilot study to evaluate the effectiveness and safety of memantine (Namenda) as augmentation therapy in patients with generalized anxiety disorder (GAD) or social anxiety disorder (SAD), who are only partial responders to selective serotonin-norepinephrine reuptake inhibitors (SNRI's) or selective serotonin reuptake inhibitors (SSRI's).

Next Previous
Search
Trial Profile

A 10 week open-label pilot study to evaluate the effectiveness and safety of memantine (Namenda) as augmentation therapy in patients with generalized anxiety disorder (GAD) or social anxiety disorder (SAD), who are only partial responders to selective serotonin-norepinephrine reuptake inhibitors (SNRI's) or selective serotonin reuptake inhibitors (SSRI's).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Memantine (Primary)
  • Indications Generalised anxiety disorder; Social phobia
  • Focus Therapeutic Use

Most Recent Events

  • 29 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 29 Sep 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
  • 16 Dec 2008 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top